Synergistic drug combination screening using a nanodroplet processing platform to enhance neuroblastoma treatment in TH-MYCN transgenic mice.

ABSTRACT: Neuroblastoma is a highly aggressive pediatric cancer with a poor prognosis, particularly in high-risk (HR) cases characterized by MYCN amplification. The severe side effects associated with high-dose chemotherapy further complicate treatment. Despite significant advancements in drug screening, traditional platforms remain limited due to their requirement for large cell quantities and their low translational success from bench to clinic. These limitations hinder the application of personalized medicine screening for patients with neuroblastoma. To address these challenges, we developed a Bioinspired Nanodroplet Processing (BioNDP) platform. This innovative platform allows for the simultaneous screening of multiple drug combinations while reducing the required number of cells to just 100 an

SUBMITTER: Liao YT 

PROVIDER: S-EPMC12284426 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature